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Abstract. Background: Restless Legs Syndrome (RLS) is one of the most common sleep 
disturbance problems in dialysis patients. In this study, we would like to explore some of 
bone and mineral marker disorder especially fibroblast growth factor-23 (FGF-23)and its 
correlation with RLS in regular hemodialysis patients. Methods: This is a cross sectional 
study design involving 71 respondents with chronic kidney disease that already had regular 
hemodialysis at Haji Adam Malik Hospital Medan. Status of RLS in this patients were being 
evaluated according to the International Restless Leg Syndrome Study Group (IRLSG) by 
interviewing and laboratory examination of FGF-23, hemoglobin (Hb), serum iron (SI), total 
iron binding capacity (TIBC), transferrin saturation (TSAT), serum ferritin, calcium (Ca) and 
phosphate (P) level. Results: Of all study subjects, 26 respondents (34.6%) diagnosed with 
RLS. Bivariate analysis result showed that there is a relationship between FGF-23, 
hemoglobin, phosphate, and transferrin saturation level with RLS. Logistic regression 
analysis used to see the most dominant factor of all. Conclusion This study conclude that 
increase in FGF-23 levels can increase the risk of RLS. However, FGF-23 is not the most 
dominant risk factor for RLS in regular hemodialysis patients. 
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Abstrak. Latar Belakang: Restless Legs Syndrome (RLS) merupakan salah satu gangguan 
tidur yang paling sering dijumpai pada pasien dialysis. Pada penelitian ini, kami ingin 
mengesksplorasi beberapa penanda gangguan tulang dan mineral terutama fibroblast 
growth factor-23 (FGF-23) dan hubungannya dengan RLS pada pasien hemodialisis reguler. 
Metode: Penelitian cross sectional ini melibatkan 71 responden dengan penyakit ginjal 
kronis yang sudah menjalani hemodialisis rutin di Rumah Sakit Haji Adam Malik Medan. 
Status RLS pada pasien ini dievaluasi sesuai dengan International Restless Leg Syndrome 
Study Group (IRLSG) melalui wawancara dan pemeriksaan laboratorium FGF-23, 
hemoglobin (Hb), besi serum (SI), total iron binding capacity (TIBC), saturasi transferrin 
(TSAT), serum ferritin, kalsium (Ca) dan tingkat fosfat (P). Hasil: Dari semua subjek 
penelitian, 26 responden (34,6%) didiagnosis dengan RLS. Hasil analisis bivariat 
menunjukkan bahwa ada hubungan antara FGF-23, hemoglobin, fosfat, dan tingkat saturasi 
transferrin dengan RLS. Analisis regresi logistik digunakan untuk melihat faktor yang paling 
dominan dari semuanya. Kesimpulan: Penelitian ini menyimpulkan bahwa peningkatan 
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kadar FGF-23 dapat meningkatkan risiko RLS. Namun, FGF-23 bukan faktor risiko paling 
dominan untuk RLS pada pasien hemodialisis reguler. 
Kata Kunci: Fibroblast Growth Factor-23, Hemodialisis, Restless Legs Syndrome 
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1 Introduction 
Hemodialysis (HD) still become the main renal replacement therapy aside from peritoneal dialysis 
(PD) and renal transplants in most countries in the world [1]. Hemodialysis (HD) aims to eliminate 
the symptoms of uremia that occur in Chronic Kidney Disease (CKD) patients. However, various 
complications can occur during HD [2]. Patients with regular hemodialysis can experience a 
variety of complaints that can directly affect the patient’s quality of life and health.(3) Restless 
Legs Sydrome (RLS) is one of the most common sleep disturbance problems in dialysis patients 
with a prevalence of up to 20% in patients with CKD [3]. Patients undergoing HD who 
experienced RLS, had a higher mortality rate than patients without RLS (32.3% vs 14.5%; p 
<0.04) with Hazard Ratio of 1.39; 95% CI 1.08-1.79 [3].  
Although the diagnosis of RLS can be established in a simple way by using questionnaires, this 
disorder is often ignored.(4)  A decrease in the prevalence of RLS in patients who have received 
kidney transplantation (4% vs 11%; P <0.001) provides an illustration that the kidney disease 
itself plays a role in the occurrence of RLS [3]. 
There have been limited studies concerned on FGF-23, a marker of Bone and Mineral Disorder 
in Chronic Kidney Disease (BMD-CKD), and RLS. The connection between iron metabolism 
with Bone and BMD-CKD related to RLS has been previously studied by Neves et al. in [4].  
Although they cannot prove the relationship between FGF-23 and the factors associated with iron 
metabolism, however, they found a correlation between several sign of bone and mineral disorders 
and iron metabolism with RLS. Patients with RLS have high phosphate levels, increased FGF-23 
levels of more than > 2000 RU/mL, vitamin D deficiency, increased PTH levels and lower 
transferrin saturation [4]. However, the pathogensesis of anemia and phosphate in correlation with 
the incidence of RLS with FGF-23 remain unclear. This study aims to determine the relationship 
of FGF-23 with RLS in regular hemodialysis patients. 
2 Research Methods 
This study is an analytic observational study with cross sectional design. Patients who had 
hemodialysis at Haji Adam Malik Hospital Medan in May - July 2019 and met the inclusion 
criteria; patients with CKD who had undergone hemodialysis for more than 3 months and were 
18 years old, were included in the study. Hospitalized patients, or patients with infections (chronic 
and severe), had malignancy, had drug or alcohol abuse, patients with neurological disorders (eg 
stroke), patients with myalgia, venous static, arthritis, leg cramps, or foot discomfort due to 
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position and stomping habits, patiens with NYHA IV congestive heart disease and having 
incomplete data, they are all excluded from the study.  
Sampling was done by using consecutive sampling technique, in this technique all subjects who 
came in sequence and met the selection criteria were included in the study until the required 
number of samples met. This study involved 71 respondents. 
 Patients who were willing to participate in this study were asked to give their written consent 
(informed consent) to take part in research. This research had been approved by the Ethics 
Commission of The Faculty of Medicine, Universitas Sumatera Utara (No: 442/TGL/KEPK FK 
USU-RSUP HAM/2019). Data of age, sex, and duration of hemodialysis were obtained from 
medical records. History of blood transfusions and use of drugs such as erythropoietin, iron 
supplementation, phosphate binders and gabapentin were noted. RLS was diagnosed by 
interviewing the patients according to the IRLSSG (International Restless Legs Syndrome Study 
Group) criteria. If the patient meets the four diagnostic criteria, the interview will continue to 
assess the RLS degree according to the International Restless Legs Syndrome Scale (IRLS) which 
has been validated in English and translated into Indonesian by the University of North Sumatra 
Language Center. Subsequent to interview, a biochemical examination consisting of FGF-23, 
hemoglobin, serum iron, total iron binding capacity (TIBC), ferritin serum, calcium, and 
phosphate from the taken blood samples was conducted. FGF-23 examination was conducted 
using the enzyme linked immunosorbent assay (ELISA) double-sandwich from Qayee 
Biochemicals with a limit of 15.6-2000 pg/ml. Other biochemical tests were conducted according 
to the recommended inspection standards. 
Data were analyzed using the SPSS-21 application. Univariate data was analyzed to determine 
the frequency distribution. Categorical variables were presented with the number or frequency (n) 
and percentage (%) and numerical variables were presented with the mean and standard deviation 
for normally distributed data, whereas numerical data that were not normally distributed were 
presented with the median. The independent variables studied were FGF-23, hemoglobin (Hb), 
serum iron (SI), total iron binding capacity (TIBC), transferin saturation (TSAT), ferritin, calcium 
(Ca) and phosphate (P) with RLS as the dependent variable. 
Statistical analysis were performed by using t-test for independent and dependent variables with 
normally distributed numeric and categorical data types, and the Mann-Whitney U test for data 
that is not normally distributed. Chi square test is used to compare the independent variable and 
the dependent variable both of which have categorical data types. If there were some requirements 
that were not fulfilled in the Chi-Square test, the Fisher Exact Test will be conducted. A value of 
p <0.05 was considered statistically significant. 
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3 Results  
This study was conducted at the Haji Adam Malik Hospital Medan involving 71 respondents who 
had regular HD. The mean age of respondents was 53.0 ± 11.04 years dominated by male by 42 
people (59.2%). Comorbid diseases mostly found were DM by 13 people (18.3%) and 
hypertension by 51 people (71.8%). Complications observed in this study were Restless Leg 
Syndrome (RLS), experienced by 26 people (36.6%) with the majority of patients having 
moderate degrees by 21 people (80.8%) followed by severe degrees by 3 people (11.5% ) and 
mild degrees by 2 people (7.7%). Respondents with RLS had a higher mean age than respondents 
without RLS (57.27 ± 11.130 vs. 53.02 ± 11.042). The age distribution of < 40 years old 
experienced less RLS but did not show statistically significant results (p=0.492). Based on sex, 
women experienced more RLS than men (55.2% vs. 31.0%), but were also not statistically 
significant (p=0.233). Neither DM nor hypertension showed a statistically significant difference 
in RLS status (p=0.879 vs. p=0.359) (Table 1). 
Table 1 Characteristics Distribution of Patients Based on Status of RLS in Regularly 
HD Patients 









0.492 1.5  (0.27 -  8.34) 
< 40   2 (28.6 %) 5 (71.4 %)   
≥ 40   24 (37.5 %) 40 (62.5 %)   
Sex   0.233 1.8 (0.68  - 4.84) 
Male 13 (31.0 %) 29 (69.0 %)   
Female 13 (44.8 %) 16 (55.2 %)   
Comorbid 
Disease 
    
DM   0.879 0.9  (0.26  - 3.14) 
Yes 5 (38.5 %) 8 (61.5 %)   
No 21 (36.2 %) 37 (63.8 %)   
Hypertension   0.359 1.6  (0.57  -  4.70) 
Yes 17 (33.3 %) 34 (66.7 %)   
No 9 (45.0 %) 11 (55.0 %)   
Notes : DM: Diabetes Mellitus; HD: Hemodialysis; Hb = Hemoglobin; Ca = Calcium; P = 
Phosphate; FGF-23 = Fibroblast Growth Factors; SF = ferritin serum; SI = Serum Iron; 
ST = Tranferin Saturation; TIBC = Total Iron Binding Capacity RLS: Restless Leg 
Syndroms. 
 
Most of the respondents with RLS have Hb levels of>10 (48.6%) (p=0.028). Respondents with 
Hb levels of <10 have 3.079 times risk for experiencing RLS [OR 95% CI (1.109 – 8.852)]. 
Respondents with Ca levels of > 9.5 suffering RLS were found more in numbers compared to 
respondents with Ca levels of ≤ 9.5 (41.9% vs. 28.6%) but it did not show statistically significant 
(p = 0.286). Respondents with phosphate levels  > 5.5 suffering RLS higher compared to 
respondents with phosphate levels ≤5.5 (47.4% vs. 24.2%) which was statistically significant (p 
= 0.044). Respondents who had a phosphate levels of > 5.5 had 2.813 times risk for experiencing 
RLS [OR 95% CI = 2.813 (1.0-7.8)]. This study found that respondents with RLS having FGF-
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23 levels > 319.5 are more than respondents with FGF-23 levels of ≤ 319.5 (48.6% vs. 25.0%) 
which showed statistically significant results (p = 0.039). Respondents who have a FGF-23 levels 
of > 319.5 have 2.883 times risk for experiencing RLS [OR 95% CI = 2.883 (1.0 - 7.7)]. This 
study also found that most respondents with RLS have higher Serum Feritin  levels, which is  ≥ 
200, compared with respondent with SF  <200 (37.5% vs. 33.3%) but was not statistically 
significant (p = 0.766). Respondents with RLS having ST levels of > 39.3 were more in number 
than respondent with ST levels of ≤ 39.3 (48.7% vs. 21.9%) which showed statistically significant 
results (p = 0.039). Respondents who have an ST levels of > 39.3 have 3,393 times risk for 
experiencing RLS [OR 95% CI = 3.3993 (1.2 - 9.7)] (Table 2). 
Table 2 Characteristics Distribution of Patients Based on Status of RLS in Regularly HD 
Patients 







Hb (g/dL)   0.028* 3.079 (1.109 – 8.852) 
< 10 18 (48.6%) 19 (51.4%)   
≥ 10 8 (23.5%) 26 (76.5%)   
Ca (mg/dL)   0.256 1.80  (0.6 – 4.9) 
≤  9.5 8 (28.6%) 20 (71.4%)   
> 9.5 18 (41.9%) 25 (58.1%)   
P (mg/dL)   0.044* 2.813 (1.0-7.8) 
≤ 5,5 8 (24.2%) 25 (75.8%)   
> 5,5 18 (47.4%) 20 (69.2%)   
FGF-23 (RU/mL)   0.039* 2.883 (1.0 – 7.7) 
≤ 319.5 9 (25.0%) 27 (75.0%)   
> 319.5 17 (48.6%) 18 (51.4%)   
SF (ng/mL)   0.766 1.20 (0.4 – 3.9) 
< 200 5 (33.3%) 10 (66.7%)   
≥ 200 21 (37.5%) 35 (62.5%)   
TSAT (%)   0.019* 3.393 (1.2-9.7) 
≤ 39.3 7 (21.9%) 20 (78.1%)   
> 39.3 19 (48.7%) 25 (51.3%)   
Notes : *(p < 0,05); Mean ± SD (Standard of Deviation); Hb = Hemoglobin; Ca = Calcium; 
P = Phosphate; FGF-23 = Fibrolast Growth Factors; SF = ferritin serum; TSAT = 
Tranferin Saturation 
 
From the bivariate analysis, more than one statistically significant variable was found in the 
respondent's RLS status, which was FGF-23, transferrin saturation, phosphate and hemoglobin 
level. To get the most dominant risk factor affecting RLS status in regular HD patients, these 
variables were included in the multiple logistic regression test analysis. This analysis showed that 
FGF-23 was not a dominant risk factor for RLS status, but Hb levels was. Hb levels of  <10 have 
a 3.613 risk for having RLS [OR = 3.613, 95% CI (1.172 – 11.138) ] which was statistically 
significant with p value of = 0.025(Table 3). 
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Table 3 Logistic Regression Test Analysis As Risk Factor Towards Status Of RLS 
Variables OR 
95% Confident Interval 
P-Value 
Lower Upper 
P >  5.5 3.056 0.106 1.010 0.052 
ST≤ 39.32 3.069 1.001 9.407 0.050 
Hb < 10 3.613 1.172 11.138 0.025* 
Notes : Hb = Hemoglobin; Ca = Calcium; P = Phosphate; FGF-23 = Fibrolast Growth Factors; 
SF = Ferritin Serum; TSAT = Tranferin Saturation;  p < 0.05*; OR = Odds Ratio. 
4 Discussion 
In this study, of 71 people who were on regular hemodialysis twice a week, 26 of them (36.6%) 
experienced RLS. Based on RLS data in America, RLS was found in 2.5-15% of the American 
population and around 2-5% in India and other Asian countries [7]. The quite varied prevalence 
in various regions may be caused by differences in race, culture, socioeconomic status and 
availability of health facilities [8]. Restless Leg syndrome or also known as Wills Ekbom Disease 
(WEB) is a neurological disease with various complaints and degrees of morbidity. The last few 
years, various studies have been carried out to study factors related to RLS. In Indonesia alone 
there is not much data about RLS.  
In the general population, the RLS ratio is 2:1 in women compared to men [7]. In this study, the 
percentage of RLS in females was higher than males (55.2% vs. 31.0%) but did not show 
statistically significant results (p = 0.233). This is consistent with studies by Wali et al in [6] in 
Saudi and Neves et al in [4] who did not find any difference in the prevalence of RLS between 
male and female hemodialysis patients.  
In this study, the age of respondents with RLS was older than non-RLS but was not statistically 
significant. RLS can be divided into primary and secondary RLS. The primary RLS has unknown 
cause while the secondary RLS is generally associated with neurological disorders, iron 
deficiency and kidney disorders. The prevalence and severity of the degree of RLS that increases 
with age leads to the degeneration process playing a role in the occurrence of RLS [6,9].  
Diabetes mellitus and hypertension were the main etiology of CKD in all developed countries and 
in many developing countries [10]. Data from the Indonesian Renal Registry (2017) shows that 
hypertension is still the most common comorbid disease in CKD patients undergoing 
hemodialysis in Indonesia with (36%) and followed by diabetes (29%) [11]. This study is also 
consistent with study conducted by Muzasti et al in 2018 in Medan, Indonesia, where the majority 
of subjects who experienced CKD were men as many as 61.8% and also suffering from comorbid 
hypertension by 75% [12].  In line with this study, hypertension is the most common disease 
suffered by 51 respondents (71.8%) and DM in 13 respondents (18.3%). This study found that 
patients with RLS having more hypertension than DM as comorbid disease (38.5% vs. 33.3%). 
Neither DM nor hypertension showed a statistically significant difference in RLS status (p = 0.879 
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vs. p = 0.359). This is in line with the study of Kim et al that did not find any difference in RLS 
status in patients with DM and patients with hypertension [9]. Both can cause kidney damage and 
anemia which is one of the risk factors of RLS but pathophysiologically, both DM and 
hypertension were not related to RLS [13].  
Most of respondents with RLS have Hb levels of <10 compared with Hb levels of >10 (48.6% vs. 
23.5%), which showed statistically significant results (p = 0.028). In the bivariate analysis it can 
also be seen that Hb levels <10 g/dL increase the risk for RLS by 3.079 times [OR 95% CI = 
3.079 (1.09 - 8.552)]. Based on logistic regression analysis it was found that Hb level was the 
most dominant risk factor for RLS status, where Hb levels of <10 had a 3.613 times risk for having 
RLS [OR = 3.613, 95% CI (1.172 – 11.138)] which was statistically significant with a p value of 
= 0.025. Molnar et al in [14] observation of 992 kidney transplant patients showed lower 
hemoglobin levels and iron deficiency in RLS patients were found in renal dialysis patients (p 
<0.05) compared to controls. Araujo et al in [15] study showed lower hemoglobin levels in RLS 
patients (p <0.05). 
In renal anemia, in addition to erythropoietin deficiency as the main cause, other contributing 
factors were iron deficiency. Therefore, before administering therapy (erythropoiesis stimulating 
agent / ESA), assessment of iron status in patients with chronic kidney disease must be done first 
[16]. The relationship between iron metabolism and dopamine transmission has been 
demonstrated, where iron deficiency causes a decrease in dopamine D2 receptor density in the 
striatum and nucleus accumbens accompanied by a decrease in the density of dopamine 
transporters [4]. This mechanism is similar to that which occurs in dialysis patients, because iron 
deficiency is commonly associated with RLS [6]. According to Filho et al in [17], the condition 
of uremia with its wide-ranging effects on cell physiology affects iron uptake in the brain barrier 
and causes iron deficiency in tissues cerebral as found in primary RLS. Iron deficiency in the 
brain causes a decrease in dopaminergic function which then encourages hyperexcitability and 
causes sensory stimulation and spontaneous motor movements in RLS [6]. 
At present, treatment of RLS include iron supplementation and administration of dopaminergic 
agonist [4]. Serum iron was higher in respondents without RLS compared to respondents with 
RLS (86.22 ± 19.676 vs. 79.77 ± 16.834) whereas TIBC levels were higher in respondents with 
RLS compared to respondents without RLS (217.42 ± 15.214 vs. 213 , 54 ± 14.058), but the SI 
and TIBC levels did not show statistically significant results with RLS status (p = 0.166 vs. p = 
0.291). Transferrin saturation, which is the result from division of serum iron and TIBC, has a 
higher mean in patients without RLS compared to respondents with RLS (39.74 ± 8.76 vs. 36.92 
± 7.52). This is in line with serum ferritin levels where respondents with RLS have a higher value 
than respondents without RLS (477.94 ± 326.704 vs. 453.99 ± 309.875), where respondents with 
RLS have more percentages with SF ≥ 200 levels compared to SF value <200 (37.5% vs. 33.3%) 
but did not show statistically significant results (p = 0.766). However, in general the 
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characteristics of all respondents had relatively sufficient iron status with serum iron levels of 
more than 65 µg / dL, transferrin saturation of more than 30%, and ferritin levels with a median 
of 340 ng / mL. Even so, there were 34.6% of respondents who suffering from RLS.  
Bone and mineral disorders in BMD-CKD patients were now being put forward as one of the new 
factors since there is an association of hyperphosphatemia and vitamin D deficiency with RLS in 
uremic patients and in the general population [4]. Dopamine mediates phosphate excretion in the 
kidneys. In theory, any dopaminergic nerve disorder can cause hyperphosphatemia [8]. However, 
the relationship between the two is still uncertain. In this study, the mean phosphate levels in RLS 
respondents was higher than respondents without RLS (5.49 ± 0.655 vs. 5.41 ± 0.582). 
Respondents who had a phosphate level of > 5.5 had a 2.813 times risk for experiencing RLS [OR 
95% CI = 2.813 (1.0-7.8)]. 
FGF-23 is increased in dialysis patients and is associated with hyperphosphatemia [18]. FGF-23 
is a marker of impaired phosphate metabolism [4]. Therefore, FGF-23 is associated with RLS. 
The mean value of FGF-23 in RLS respondents was higher compared to respondents without RLS 
(499.85 ± 470.650 vs. 312.9 ± 76.180) where there are more respondents with RLS who had FGF-
23 levels of > 319.5 compared to patients with FGF- levels of ≤319.5 (48.6% vs. 25.0%) which 
showed statistically significant results (p = 0.039). The same conditions were found in this study 
population. Respondents who have FGF-23 levels> 319.5 have a 2.883 times risk to experience 
RLS [OR 95% CI = 2.883 (1.0 - 7.7)]. 
In individuals with normal kidney function, iron deficiency can stimulate production and 
clearance of intact FGF-23 which results in terminal FGF-23 fraction. In CKD patients, there is a 
disruption to the clearance, so that almost all FGF-23 is intact [4]. In multivariate analysis of this 
study, FGF-23 was ultimately not a dominant risk factor for RLS. This may be due to the fact that 
respondents have relatively sufficient iron content and so is the mean phosphate value which 
almost hit the target value according to KDIGO guidelines given the iron and phosphate status is 
closely related to FGF-23. On the other hand, the direct effect of FGF-23 on RLS cannot be ruled 
out. Increased FGF-23 is associated with hematopoiesis [18]. FGF-23 is proven to be one of the 
causes of renal anemia [19]. The inhibition of the FGF-23 activity will stimulate erythropoiesis, 
overcome anemia and iron deficiency in rats with CKD [19]. In a previous study by Neves et al. 
in [4], FGF-23 was associated with RLS where with an increase in FGF-23 levels cause a 3.16 
times risk of experiencing RLS (95% CI 3.16 (2.13-4.18) which was statistically significant (p < 
0.0001).  
Another marker of BMD-CKD is calcium. In this study, mean calcium levels were not too 
different between patient with and without RLS (9.77 ± 0.78 vs. 9.61 ± 0.76). There are more 
patients with RLS who had calcium levels of > 9.5 than respondents with calcium levels of <9.5 
mg / dL (41.9% vs. 28.6%), but there were no statistically significant differences. Neither in the 
study of Wali et al. in [6] nor by Araujo et al. in [15] found a significant difference in calcium 
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levels and RLS in hemodialysis patients. The role of calcium cannot be concluded and with a 
larger sample, it is expected to answer the existing problem. 
Limitation of this study is that this study was only conducted in one place (single-center). 
Hemodialysis patients with decreased kidney function result in the emergence of various 
complications can cause bias in the study. In addition, lack of data on drug use such as 
benzodiazepines, gabapentin, tricyclic antidepressants, calcium channel blockers whose role 
cannot be separated from RLS. Finally, this study uses a cross-sectional design, therefore a causal 
relationship cannot be proven. Research into factors related to RLS in hemodialysis patients is 
still needed and it is recommended to use samples from various hemodialysis (multi-center) 
centers. 
5 Conclusion 
From the research that has been done, it can be concluded that there is a correlation between FGF-
23 levels with RLS in regular hemodialysis patients where an increase in FGF-23 levels is 2.883 
times risk for having RLS. Based on bivariate analysis, besides FGF-23, hemoglobin, phosphate 
and transferrin saturation levels have a relationship with Restless Legs Syndrome (RLS). Based 
on multivariate analysis, hemoglobin (Hb <10) is the dominant risk factor of RLS. 
RLS is increased and is often found in patients with regular hemodialysis, but often undiagnosed. 
There is no data on the prevalence of hemodialysis in Indonesia. Therefore, screening of health 
facilities that provide renal replacement therapy needs to be done, especially hemodialysis.  
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